Redefining the Standard of Care for Low-Grade Serous Ovarian Cancer
Low grade serous ovarian cancer (LGSC) is rare being about 5% of all ovarian cancer, it has many differences to the common high-grade disease and increasingly it is being treated as a separate disease with targeted therapy appropriate for its distinct molecular features.
Recognition of this has led to a proposed new standard of care which includes complete understanding of the individual tumour with appropriate hormonal suppression for some and use of MEK, (Mitogen extracellular Kinase) inhibitors, these target protein pathways which increase cancer growth. This treatment may be used alone or in combination with platinum chemo.
Minimally invasive surgical techniques may be used which increases quality of life for the patient. Genetic screening should be included as part of the care with the intent of enabling personalised care.
This new regime should increase survival, especially for the sub-group of younger women who are more prone to develop this form of ovarian cancer.
No comments:
Post a Comment